Goldman Sachs Maintains Buy on Beta Bionics, Lowers Price Target to $17
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
Goldman Sachs analyst David Roman maintains Beta Bionics (NASDAQ:BBNX) with a Buy and lowers the price target from $19 to $17.
Goldman Sachs analyst David Roman maintains Beta Bionics (NASDAQ:BBNX) with a Buy and lowers the price target from $19 to $17.